Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7250
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1117–1128 of 7,250 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Conditions
Selected Advanced Solid Tumors
Interventions
MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more
Conditions
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more
Conditions
Solid Tumors
Interventions
ZL-1310
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
San Francisco, California • Peoria, Illinois • Detroit, Michigan + 9 more
Conditions
Endometrial Adenocarcinoma
Interventions
ACR-368, Gemcitabine, OncoSignature
Drug · Diagnostic Test
Lead sponsor
Acrivon Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
69
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Apnea in Elderly

NCT02703220
Conditions
Sleep Apnea, Elderly Adults
Interventions
Hyperoxia/oxygen, Acetazolamide, Finasteride
Other · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Interventions
Roflumilast, Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 23 more
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
15 Years to 40 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
225
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Interventions
Zilovertamab vedotin, Nemtabrutinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more
Terminated Phase 4 Interventional Results available

Optimal Treatment for Recurrent Clostridium Difficile

NCT02667418
Conditions
Clostridium, Difficile, Fidaxomicin, Vancomycin
Interventions
Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Active, not recruiting No phase listed Observational

Evaluating the InPen in Pediatric Type 1 Diabetes

NCT05515939
Conditions
Type 1 Diabetes
Interventions
InPen Insulin Pen
Device
Lead sponsor
Wayne State University
Other
Eligibility
13 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
Interventions
Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Long Beach, California • West Los Angeles, California • West Haven, Connecticut + 5 more
Conditions
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Interventions
Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor
Drug · Biological
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more